Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Sorafenib (Primary) ; Cisplatin; Paclitaxel
- Indications Early breast cancer
- Focus Therapeutic Use
- 06 Aug 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record
- 30 Apr 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
- 12 Nov 2014 Planned End Date changed from 1 Feb 2015 to 1 Aug 2015, as reported by ClinicalTrials.gov record.